Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin
Alexa Thibodeau1, Nambi Nallasamy1
1Department of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA.
Abstract:
Enfortumab vedotin is an antibody-drug conjugate that was recently granted accelerated US Food and Drug Administration approval for the treatment of locally advanced or metastatic urothelial cancer. Early clinical trials identified blurry vision, increased lacrimation and other events associated with dry eye as potential side effects. We report a case of bilateral anterior subcapsular cataract development following initiation of enfortumab vedotin. Enfortumab vedotin is not previously known to cause cataract development or progression and, thus, our patient's presentation may reflect the first report of an undocumented adverse effect of this novel agent.
Insights
Enfortumab vedotin, used for advanced urothelial cancer, may cause cataracts. This is the first reported case of this potential side effect, highlighting a new safety concern for this novel cancer therapy.
Area of Science:
- Oncology
- Ophthalmology
- Pharmacology
Background:
- Enfortumab vedotin recently received accelerated FDA approval for advanced urothelial cancer.
- Known side effects include dry eye symptoms like blurry vision and increased lacrimation.
Observation:
- A patient treated with enfortumab vedotin developed bilateral anterior subcapsular cataracts.
- This cataract development occurred after the initiation of the drug.
Findings:
- Cataract development is not a previously documented adverse effect of enfortumab vedotin.
- This case may represent the first report of enfortumab vedotin-induced cataracts.
Implications:
- This finding suggests a potential undocumented adverse effect of enfortumab vedotin.
- Further investigation is warranted to confirm the association between enfortumab vedotin and cataract formation.
